Fig. 5

Effect of the nivolumab treatment on TILs. a Flow cytometry analyses of TILs in tumors from the nivolumab-treated and control groups. b IHC analyses of CD4, CD8, PD-L1, PD-1, GZMB, and IFN-γ in the tumors and lungs of the nivolumab-treated and control groups (magnification at × 400). Data are presented as the mean ± S.D. (n = 5) **P < 0.01, ***P < 0.001 by Student’s t test